Portola Pharmaceuticals Profit Margin

The latest profit margin for PTLA is -232.73% as of March 2020. That compares with -618.45% in the prior-year period — up 62.4% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Portola Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, PTLA's profit margin moved from -618.45% to -232.73% — a 62.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Portola Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, PTLA currently prints -232.73% for profit margin, while the sector average sits near 21.34%. That is roughly 1190.8% below the sector mean. Large gaps often invite a closer look at Portola Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Portola Pharmaceuticals converts resources into returns. At -232.73%, PTLA may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -618.45% in the prior-year period — up 62.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PTLA's profit margin (-232.73%), review year-over-year change from -618.45%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.